Spinning out Sitryx

Why GSK decided to spin out immunometabolism company Sitryx with $30M series A

With a $30 million series A round and a pipeline of immunometabolism programs, Sitryx Therapeutics Ltd. became the first start-up to emerge from the Immunology Network at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK).

The round, which closed on Oct. 8, was co-led

Read the full 399 word article

User Sign In